HOXA9 tracking reveals RBM5 dual function and therapeutic potential for acute myeloid leukemia

The protein HOXA9 is overexpressed in most acute myeloid leukemia (AML) cases and is associated with poor patient outcomes. However, HOXA9 is a difficult protein to target therapeutically, so researchers at St. Jude Children’s Research Hospital looked for ways to extinguish it indirectly.

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart
This website uses cookies and asks your personal data to enhance your browsing experience.